

CS/NSE/ AFR/BOOK-CL
May 30, 2011

TO
THE MANAGER
LISTING DEPARTMENT
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
EXCHANGE PLAZA, BANDRA KURLA COMPLEX
BANDRA (E), MUMBAI – 400 051

Dear Sir/Madam,

Stock Code – SUVEN-EQ

Sub: 1) Notification of Audited Financial Results for the Financial-year ended 31st March 2011 – Clause 41
2) Dividend Recommendation – Clause 20
3) Closure of Register of Members & Share Transfer Books -- Clause-16

.....
1) Notification of Audited Financial Results for the 4th quarter ended 31/03/2011 and the Audited Annual Results for the Financial-year ended 31st March 2011-Clause 41 and other information

We are forwarding here with Audited Financial Results for the 4th quarter ended 31/03/2011 and Audited Annual Financial Results of our Company for the financial year 2010-2011, in the prescribed Proforma, as required under Clause-41 of the listing agreement as amended. The Board of Directors of our company has taken on record the enclosed 4th quarter and Annual Audited Financial Results for the financial year 2010-2011 in its meeting held today i.e. 30th May, 2011.

2) Dividend Recommendation – Clause 20

The Board of Directors in its meeting held today i.e. 30th May, 2011, has also recommended Dividend Re 0.25 paise per equity share of face value of Re 1/- each (25%) for the financial year ended 31/03/2011 the dividend will be paid on and from 28th August, 2011, subject to the approval of Members in ensuing Annual General Meeting.

Brief Financials as required to be furnished under clause 20 are as follows:



Suven Life Sciences Limited

- 1 -

(Rs in lakhs)		
Particulars	Current Year Ended 31/03/2011	Previous Year ended 31/03/2010
Sales and other incomes	15222.57	13388.83
Gross Profit	1480.51	1393.73
Less: Interest	610.52	494.03
Depreciation	544.55	529.14
Profit before Tax	325.44	370.55
Less: Provision for Taxation	(714.51)	(329.51)
Profit after Tax	1039.95	700.06
Add: Balance brought forward	1764.81	1473.55
Profit available for appropriation	2804.76	2173.61
APPROPRIATIONS:		
Dividend	291.83	289.69
Dividend tax	47.34	48.11
Difference in final dividend plus tax (09-10)	1.97	0.00
Transfer to General Reserve	110.00	71.00
Balance carried forward	2353.62	1764.81

3) Closure of Register of Members & Share Transfer Books -- Clause-16

Pursuant to clause 16 of the Listing agreement, we hereby notify the Book Closure dates for the Register of members and Share Transfer as under.

Security Code	Type of Security & Paid-up value	Book-Closure		Purpose
		From	To	
SUVEN-EQ	Equity Shares Rs 1.00 each	03/08/2011	05/08/2011	AGM & Dividend Declaration

The Annual General Meeting of the Company will be held on Saturday the 13th day of August 2011

Please find enclosed Press release of our company. We request you to take these Documents on your Records

Thanking You,
Yours faithfully,
For **SUVEN LIFE SCIENCES LIMITED**


K HANUMANTHA RAO
Company Secretary



Going beyond Commitment

SUVEN

LIFE SCIENCES LIMITED

Serene Chambers, Road No.7, Banjara Hills, Hyderabad- 500 034

AUDITED FINANCIAL RESULTS FOR IV Qtr FOR THE YEAR 2010-11

(Rs. in lacs)

Sl. No.	PARTICULARS	THREE MONTHS ENDED 31.03.2011	Corresponding THREE MONTHS ENDED 31.03.2010	CURRENT ACCOUNTING YEAR ENDED AUDITED 31.03.2011	PREVIOUS ACCOUNTING YEAR ENDED AUDITED 31.03.2010
1	Income from Sales & Services:	4571.04	3627.03	15104.22	12982.21
	Less : Excise duty	6.42	8.85	60.84	51.06
	Net Income from Sales & Services:	4564.62	3618.18	15043.38	12931.15
2	Total Expenditure				
	a) Decrease (Increase) in stock in trade	(29.33)	(203.37)	(53.43)	(408.27)
	b) Consumption of raw materials	1848.29	1267.47	5549.85	4251.41
	c) Purchase of traded goods	0.00	37.82	0.00	44.84
	d) Personnel cost	532.31	467.13	1782.08	1534.10
	e) Other expenditure - Manufacturing Exps	609.70	433.57	2082.72	1592.87
	- Selling Exps	121.74	50.76	261.95	192.75
	- Administrative Exps	259.78	299.53	1029.44	1002.23
	- R & D Exps	766.74	1031.09	3114.35	3415.07
	- Depreciation	136.16	131.66	544.55	529.14
	- Provision for Derivatives MTM losses	0.00	0.00	0.00	50.49
	Total expenditure :	4243.39	3515.66	14311.51	12204.63
3	Profit from operations before Interest & Exception items (1-2)	321.23	102.52	731.87	726.52
4	Other Income	82.82	22.17	125.74	49.39
5	Profit before Interest & Exceptional items (3+4)	404.05	124.69	857.61	775.91
6	Interest	142.76	111.90	532.17	405.37
7	Profit after Interest but before Exceptional items (5-6)	261.29	12.79	325.44	370.54
8	Exceptional items	0.00	0.00	0.00	0.00
9	Profit/Loss before tax (7-8)	261.29	12.79	325.44	370.54
10	Tax expense(inclusive of Def tax)	(88.77)	(145.22)	(714.50)	(329.50)
11	Net Profit (+)/Loss(-) after tax (9-10)	350.06	158.01	1039.94	700.04
12	Extraordinary items	0.00	0.00	0.00	0.00
13	Net Profit (+)/Loss(-)	350.06	158.01	1039.94	700.04
14	Paid-up equity share capital	1167.32	1158.74	1167.32	1158.74
15	Reserves excluding revaluation Reserve	---	---	---	10647.29
16	a) Basic and diluted E P S before extra ordinary items	0.30	0.14	0.89	0.60
	b) Basic and diluted E P S after extra ordinary items to date and for the previous year (not annualised)	0.30	0.14	0.89	0.60
	(Face value Rs.1)	(Face value Rs.1)	(Face value Rs.1)	(Face value Rs.1)	(Face value Rs.1)
17	Public share holdings	42858960	43219372	42858960	43219372
	Percentage of Share holding	36.72%	37.30%	36.72%	37.30%
18	Promoters and promoter group Shareholding				
	a) Pledged / Encumbered - Number of shares	NIL	NIL	NIL	NIL
	- Percentage of Shares(on promoter & promoter group)	NIL	NIL	NIL	NIL
	- Percentage of Shares(on total share capital of the company)	NIL	NIL	NIL	NIL
	b) Non- Encumbered - Number of shares	73873028	72655028	73873028	72655028
	- Percentage of Shares(on promoter & promoter group)	100.00%	100.00%	100.00%	100.00%
	- Percentage of Shares(on total share capital of the company)	63.28%	62.70%	63.28%	62.70%

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED

1	SEGMENT REVENUE :-				
a)	Manufacturing (CRAMS)	3971.60	2710.23	12675.22	9632.50
b)	Services (DDDSS)	599.45	893.60	2429.01	3326.52
c)	Research & Development	0.00	23.20	0.00	23.20
	Net Sales from Operations	4571.05	3627.03	15104.23	12982.22
2	SEGMENT RESULTS :-				
	Profit/(Loss) before tax and interest:				
a)	Manufacturing (CRAMS)	1089.22	511.14	3494.25	2727.48
b)	Services (DDDSS)	192.58	567.99	1063.51	2127.09
c)	Research & Development	(766.74)	(1008.08)	(3114.35)	(3392.80)
	TOTAL	515.06	71.05	1443.41	1461.77
Less:	i) Interest	142.76	111.90	532.17	405.37
	ii) Other Un- allocable expts net off un- allocable Income	111.01	(53.64)	585.80	685.85
	Total Profit Before Tax	261.29	12.79	325.44	370.55
3	CAPITAL EMPLOYED				
	(Segment assets - Segment Liabilities)				
a)	Manufacturing (CRAMS)	12075.70	11190.40	12075.70	11190.40
b)	Services (DDDSS)	629.97	927.43	629.97	927.43
c)	Research & Development	3506.95	3056.17	3506.95	3056.17
d)	Net assets which are not segmented and used commonly	3036.80	1638.29	3036.80	1638.29
	TOTAL	19249.42	16812.29	19249.42	16812.29

Notes: 1) The above audited results were approved and taken on record at the Board of Directors' meeting held on 30 May '2011.

2) Status of investor grievance :- Opening bal : 0, Received : 36, Resolved : 36, Closing bal : 0.

3) Previous's years figures have been regrouped / reclassified whenever necessary.

For Suven Life Sciences Ltd

Venkat Jasti - Chairman & CEO

Place : Hyderabad.
Date : 30.05.2011.




**SUVEN****LIFE SCIENCES LIMITED****Statement of Assets & Liabilities as per clause 41(V)(h) as per Listing agreement***(Rs. In lacs)*

Particulars	Year ended(31/03/2011)	Corresponding Year ended in the previous year(31/03/2010)
	Audited/Unaudited	Audited/Unaudited
SHAREHOLDER'S FUNDS:		
(a) Capital	1167.32	1158.74
(b) Reserves and Surplus	11506.42	10647.28
LOAN FUNDS	6575.68	5006.27
TOTAL	19249.42	16812.29
APPLICATION OF FUNDS :		
FIXED ASSETS	10907.34	11296.10
INVESTMENTS	2039.03	1159.85
CURRENT ASSETS, LOANS AND ADVANCES		
(a) Inventories	3336.56	3049.00
(b) Sundry Debtors	3137.39	3260.99
(c) Cash and Bank balances	294.63	223.09
(d) Other current assets	9.75	7.95
(e) Loans and Advances	1872.10	1433.67
(f) Deferred Tax Asset (Net)	766.58	44.26
Less: Current Liabilities and Provisions		
(a) Liabilities	3050.44	3551.84
(b) Provisions	63.52	110.78
Miscellaneous expenditure (not written off or adjusted)	0.00	0.00
Profit & Loss account	0.00	0.00
TOTAL	19249.42	16812.29

For Suven Life Sciences Ltd

Venkat Jasti - Chairman & CEO

Dated : 30/05/2011



SUVEN Life Sciences



News Release

Suven Spends 20.5% of Revenue on R&D PAT up by 48.55% for the year ending March 2011

HYDERABAD, INDIA (May 30, 2011) – **SUVEN LIFE Sciences Limited**, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its audited financial results for the year ended 31 Mar 2011 as well as quarter ended Mar' 2011. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on May 30, 2011 at Hyderabad.

Financial Highlights for the 4th Quarter ended Mar' 2011:

Growth in revenue	Rs 4647 lacs	vs. Rs 3640 lacs	--	27.66%
Growth in PAT	Rs 350 lacs	vs. Rs 158 lacs	--	121.54%
Growth in EBITDA	Rs 540 lacs	vs. Rs 256 lacs	--	110.73%

Financial Highlights for the full year ended Mar' 2011:

Growth in revenue	Rs 15169 lacs	vs. Rs 12980 lacs	--	16.86%
Growth in PAT	Rs.1040 lacs	vs. Rs 700 lacs	--	48.55%
Growth in EBITDA	Rs 1402 lacs	vs. Rs.1305 lacs	--	7.44%

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 767 lacs (16.5% on revenue) for the quarter ended Mar' 2011 and Rs. 3114 lacs (20.53% on revenue) for the year ended Mar' 2011 .

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. **The Company has twelve (12) internally-discovered therapeutic drug candidates** currently in pre-clinical stage of development targeting conditions such as ADHD, Dementia, Depression, Huntington's disease, Parkinson's disease and obesity in addition to **developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.**

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

